No Data
No Data
No Data
No Data
No Data
Silence Therapeutics Plc's (NASDAQ:SLN) Market Cap Touched US$1.1b Last Week, Benefiting Both Retail Investors Who Own 27% as Well as Institutions
Key Insights Silence Therapeutics' significant retail investors ownership suggests that the key decisions are influenced by shareholders from the larger public 54% of the business is held by the top
Simply Wall StApr 22 20:01
Silence Therapeutics Announces JAMA Publication Of Additional APOLLO Phase 1 Data For Zerlasiran In Subjects With Elevated Lipoprotein(a)
Silence Therapeutics plc, Nasdaq: SLN ("Silence" or the "Company"), an experienced and innovative biotechnology company committed to transforming people's lives by silencing diseases through precision
BenzingaApr 8 23:49
Brokers Are Upgrading Their Views On Silence Therapeutics Plc (NASDAQ:SLN) With These New Forecasts
Shareholders in Silence Therapeutics plc (NASDAQ:SLN) may be thrilled to learn that the analysts have just delivered a major upgrade to their near-term forecasts. The analysts greatly increased thei
Simply Wall StMar 18 18:08
Analysts Are Upgrading Silence Therapeutics Plc (NASDAQ:SLN) After Its Latest Results
Yahoo FinanceMar 16 20:29
Silence Therapeutics Plc (NASDAQ:SLN) Q4 2023 Earnings Call Transcript
Yahoo FinanceMar 15 23:56
These Analysts Boost Their Forecasts On Silence Therapeutics After Full Year 2023 Results
Silence Therapeutics Plc (NASDAQ:SLN) reported a loss for 2023 on Wednesday. The company reported a loss per share of (38.9) pence for 2023, narrower than the (41.9) pence loss per share a year ago, a
BenzingaMar 15 02:01
No Data
No Data